Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment - GlobeNewswire

Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment  GlobeNewswire

Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases